2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study

H.Wildiers; L.Dirix; P.Neven; A.Prové; P.Clement; F.Amant; R.Paridaens

首页> 外文期刊>European Journal of Cancer Supplements >2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study

【24h】

2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study

机译：2083 POSTER对高危乳腺癌患者进行剂量密集的顺序FEC多西他赛方案辅助治疗是可行的–一项随机，开放标签的II期研究结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2007年第4期| 共1页
作者
H.Wildiers; L.Dirix; P.Neven; A.Prové; P.Clement; F.Amant; R.Paridaens;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献

1. 2095 POSTER A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients [J] . S.Kahan, S.Spanik, M.Wagnerova, European Journal of Cancer Supplements . 2007 ,第4期

机译：2095年海报：一项随机，开放标签的CECOG II期研究，针对早期乳腺癌患者的剂量密集型FEC 75与FEC 90作为辅助治疗
2. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients [J] . Moebus V., von Minckwitz G., Jackisch C., Annals of oncology: official journal of the European Society for Medical Oncology . 2017 ,第8期

机译：德国佐剂互动节点阳性研究（增益）：一种相对于高风险早期乳腺癌患者中的两种剂量 - 致密的方案（IDDEPC与DDEC-PWX）的III期试验
3. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. [J] . Fountzilas G, Skarlos D, Dafni U, Annals of oncology: official journal of the European Society for Medical Oncology . 2005 ,第11期

机译：高风险可手术乳腺癌患者术后进行表阿霉素联合阿霉素联合或不联合紫杉醇的剂量密集序贯化疗：希腊合作肿瘤小组进行的一项随机III期研究。
4. Pilot patient study with the Wavelia Microwave Breast Imaging system for breast cancer detection: Clinical feasibility and identified technical challenges [C] . A. Fasoula, L. Duchesne, B.M. Moloney, European Conference on Antennas and Propagation . 2020

机译：使用Wavelia微波乳房成像系统进行的乳腺癌患者试验研究：临床可行性和确定的技术挑战
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Dose-dense sequential adjuvant chemotherapy followed as indicated by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial [O] . George Fountzilas, Urania Dafni, Christos Papadimitriou, 2014

机译：如所示在早期乳腺癌患者中进行了剂量密集的序贯辅助化疗随后是曲妥珠单抗治疗了一年：希腊合作肿瘤小组随机III期临床试验的5年中位随访首次报道
7. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 [O] . G. Fountzilas, U. Dafni, H. Gogas, 2008

机译：高风险乳腺癌患者的术后剂量 - 致密顺序化疗，高风险乳腺癌患者：Hellenic合作肿瘤学院的安全分析随机分配III审判他10/00

2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study

著录项

相似文献

相关主题

期刊订阅